Connections Pyxis Oncology, Inc.

PYXS

US7473241013

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-21 pm EDT			5-day change	1st Jan Change
1.710 ^USD	+0.59%		+0.59%	+48.70%

Apr. 17	Pyxis Oncology Presents New Preclinical Data on MICVO Combination Therapy in HNSCC Model	CI
Mar. 23	Pyxis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

14

Listed companies

12

Private companies

39

Insiders

Relation chart of related listed companies: Pyxis Oncology, Inc.

Active Relations

Past Relations

Related listed companies: Pyxis Oncology, Inc.

BAYER AG

Jürgen Eckhardt

SYNDAX PHARMACEUTICALS, INC.

Michael Metzger

IMUGENE LIMITED

Jakob Dupont

XENON PHARMACEUTICALS INC.

Darren Cline

SYMBIO PHARMACEUTICALS LIMITED

Jay Feingold

BOLT BIOTHERAPEUTICS, INC.

Jakob Dupont

PLIANT THERAPEUTICS, INC.

Darren Cline

ACRIVON THERAPEUTICS, INC.

Santhosh Palani

CYBIN INC.

Freda Lewis-Hall

METAGENOMI THERAPEUTICS, INC.

Jürgen Eckhardt

ORCHESTRA BIOMED HOLDINGS, INC.

DIANTHUS THERAPEUTICS, INC.

Jennifer Ruff

Active Relations

Past Relations

Relationship chart for related private companies: Pyxis Oncology, Inc.

Active Relations

Past Relations

Related private companies: Pyxis Oncology, Inc.

Longwood Fund Management LLC

Investment Managers

Christoph Westphal

David Steinberg

eGenesis, Inc.

Medical/Nursing Services

Jürgen Eckhardt

Lucio Iannone

Triumvira Immunologics, Inc.

Pharmaceuticals: Major

Jürgen Eckhardt

Shaan Gandhi

Agent Capital LLC

Investment Managers

Geeta Vemuri

Jak Knowles

ClostraBio, Inc.

Biotechnology

John Flavin

Ritu Shah

Khloris Biosciences, Inc.

Miscellaneous Commercial Services

Jürgen Eckhardt

Lucio Iannone

Leaps by Bayer

Investment Managers

Jürgen Eckhardt

Lucio Iannone

Immunitas Therapeutics, Inc.

Biotechnology

Vesigen, Inc.

Biotechnology

Jak Knowles

Jürgen Eckhardt

Lucio Iannone

Portal Innovations LLC

Investment Managers

John Flavin

Ritu Shah

Incendia Therapeutics, Inc.

Pharmaceuticals: Major

Shaan Gandhi

Christopher O’Donnell

Carbon Biosciences, Inc.

Biotechnology

David Steinberg

Geeta Vemuri

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Pharmaceuticals: Major	10
Biotechnology	9
Investment Managers	4
Miscellaneous Commercial Services	1
Medical/Nursing Services	1
Medical Specialties	1

Countries of related companies

United States	19
Canada	3
Germany	2
Japan	1
Australia	1

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Employees

Sector

Biotechnology & Medical Research

More about the company